In EGFR/HER2-inhibitor resistant breast cancer cells, there is enhanced autophagy in response to the inhibitor, which can be switched to apoptosis by BECN1 depletion (Han et al., 2013). The gene discussed is BECN1; the disease is breast carcinoma.